AcuFocus, Inc. delivers breakthrough small aperture intraocular products to address diverse unmet needs in eye care and help patients achieve their best personal vision. The IC-8 Apthera IOL (known as the IC-8 IOL in global markets) is approved in the United States for the treatment of cataracts. The lens received CE mark in 2015 and is available in Australia, New Zealand, Singapore, and select markets across Europe.

Irvine

AcuFocus, Inc.

Bausch + Lomb Corporation is a leading global eye health company committed to improving people’s vision. The company focuses on developing innovative products for vision correction, surgical procedures, and consumer eye care. It operates with a long-standing dedication to enhancing the visual health of patients worldwide. Bausch + Lomb is recognized for its advanced technology and quality in eye care solutions.

https://www.bausch.com/

Bausch + Lomb Corporation

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

Bausch + Lomb Acquires Acufocus, Inc.

Bausch + Lomb Acquires Acufocus, Inc.

Company Info